DRMA: Dermata Corp Cash Calculated per Single Share

Dermata Therapeutics (DRMA) develops unique rosacea treatments leveraging bioengineering patents and FDA approval. However, a lack of diversification and a high burn rate create significant risks. Since the company lacks a stable revenue stream, its survival depends on new equity offerings. The historical trend of the cash cushion per share on the GURU.Markets chart clearly confirms this, and the value of 1.02 characterizes this level.
Comprehensive metric breakdowns and analytics for Dermata Therapeutics, Inc. (DRMA)

This metric determines the level of liquidity available to each shareholder to ensure the business's financial autonomy. The trend in actual cash per share reflects the intensity of cash reserve depletion. The metric is calculated by dividing the total amount of cash by the number of shares outstanding, which allows for an assessment of the company's resilience to market shocks. For Dermata Therapeutics (DRMA), such reserves are critical for the development of premium anti-inflammatory skin medications.